In arrivo
Drug Discovery & Pharmaceutical Biotechnology
Porta un target dall'ipotesi al primo uso sull'uomo.
Il corso completo
- moduli
- 90
- argomenti
- 900
- min per lezione
- 15
45%
del carico globale di malattia attuale si potrebbe affrontare con la scienza già concepibile oggi.
Quello che saprai fare.
Giudica se un target vale la pena
Tappa 1 · Target Discovery & Validation
Fai screening senza cadere negli artefatti
Tappa 2 · Models, Assays & Screening
Leggi le relazioni struttura-attività
Tappa 3 · Molecular Design & Medicinal Chemistry
Scegli tra anticorpo, oligo e terapia cellulare
Tappa 4 · Biologics & Advanced Modalities
Scarta presto un candidato debole
Tappa 5 · Developability, Safety & Candidate Selection
Leggi onestamente un risultato di fase II
Tappa 6 · Clinical Development & Regulation
Sette tappe.Una salita costante.
Target, hit, lead, candidato — poi il trial che ti dice la verità.
90moduli
in 7 tappe
900argomenti
≈ 10 per modulo
≈225ore
in lezioni da 15 minuti
≈2,5anni
≈15mesi
≈7mesi
per finire l'intero corso
- 1
Target Discovery & Validation
Questo target è davvero reale?
9 moduli · 90 argomenti · ≈ 23 h
- 2
Models, Assays & Screening
Saggi, screening e i loro artefatti
18 moduli · 180 argomenti · ≈ 45 h
- 3
Molecular Design & Medicinal Chemistry
Cosa rende una molecola un farmaco
14 moduli · 140 argomenti · ≈ 35 h
- 4
Biologics & Advanced Modalities
Anticorpi, RNA, cellule, coniugati
17 moduli · 170 argomenti · ≈ 43 h
- 5
Developability, Safety & Candidate Selection
Esposizione, sicurezza, il no netto
18 moduli · 180 argomenti · ≈ 45 h
- 6
Clinical Development & Regulation
Studi clinici, autorità, evidenze
11 moduli · 110 argomenti · ≈ 28 h
- 7
Portfolio, Partnerships & Capstone
Brevetti, partner, il tuo programma
3 moduli · 30 argomenti · ≈ 8 h
Mesi
0612180369024
MesiTraguardo · ≈ 2,5 anni · ≈ 15 mesi · ≈ 7 mesi
Ore e mesi sono stime: una lezione da 15 minuti per argomento, ogni giorno.
Ogni modulo.Ogni argomento.
I titoli di moduli e argomenti restano in inglese, la lingua in cui lavora questo settore.
Tappa 1
Target Discovery & Validation
Questo target è davvero reale?
9 moduli · 90 argomenti
1Scope of Drug Discovery and Pharmaceutical Biotechnology10 argomenti
- Discovery, Preclinical Development, and Clinical Development
- Small Molecules, Biologics, and Advanced Therapeutic Modalities
- Target-Based and Phenotype-Based Discovery
- Therapeutic Hypotheses and Evidence Progression
- Discovery Tools, Research Probes, and Drug Candidates
- Product Quality, Biological Activity, and Clinical Benefit
- Multidisciplinary Responsibilities Across Development Stages
- Interfaces with Pharmacology and Disease-Specific Therapeutics
- Interfaces with Genetic Engineering and Biomanufacturing
- Decision Gates from Initial Concept to an Approved Product
2Unmet Medical Need and Indication Selection10 argomenti
- Defining the Disease and Intended Patient Population
- Current Treatment Options and Their Limitations
- Disease Burden and Patient-Relevant Outcomes
- Natural History and Progression Patterns
- Heterogeneity Within a Diagnostic Category
- Treatment Setting and Place in Therapy
- Prevention, Disease Modification, and Symptom Control
- Feasibility of Demonstrating Clinical Benefit
- Patient and Clinician Input into Development Priorities
- Selecting an Indication with a Testable Development Rationale
3Target Product Profiles and Development Objectives10 argomenti
- Intended Use and Desired Therapeutic Benefit
- Minimum Acceptable and Preferred Product Characteristics
- Route of Administration and Dosing Burden
- Efficacy, Safety, and Tolerability Goals
- Onset, Duration, and Reversibility of Effect
- Patient Selection and Diagnostic Requirements
- Storage, Delivery Device, and Care-Setting Constraints
- Differentiation from Existing and Emerging Treatments
- Translating Product Goals into Candidate Selection Criteria
- Updating the Product Profile as Evidence Accumulates
4Disease Biology and Therapeutic Hypothesis Formation10 argomenti
- Causal Mechanisms and Associated Biological Changes
- Disease Initiation, Maintenance, and Progression
- Cell Types and Tissue Compartments Involved
- Protective Responses and Pathological Responses
- Intervention Timing and Disease Stage
- Pathway Redundancy and Compensatory Mechanisms
- Genetic and Environmental Contributions
- Mechanistic Models and Competing Explanations
- Falsifiable Predictions of Therapeutic Intervention
- Evidence Needed Before Committing to a Discovery Program
5Human Genetics in Target Discovery10 argomenti
- Disease-Associated Variants and Candidate Targets
- Loss-of-Function and Gain-of-Function Evidence
- Rare Variants and Common Variant Associations
- Causal Gene Assignment at Associated Loci
- Direction of Effect and Therapeutic Modulation
- Natural Human Variation as Evidence of Target Tolerance
- Population Diversity and Generalizability
- Genetic Association and Therapeutic Causality
- Mendelian Randomization Concepts and Limitations
- Integrating Genetic Findings with Experimental Validation
6Molecular Profiling for Therapeutic Discovery10 argomenti
- Disease-Associated Transcriptional Programs
- Protein Abundance and Functional State
- Metabolic Changes and Therapeutic Opportunities
- Single-Cell Profiles and Disease-Relevant Populations
- Spatial Context and Tissue Organization
- Longitudinal Changes During Disease Progression
- Perturbation Signatures and Mechanistic Comparisons
- Confounding by Cell Composition and Treatment History
- Convergent Evidence Across Profiling Modalities
- Turning Molecular Associations into Testable Drug Hypotheses
7Target Prioritization and Evidence Assessment10 argomenti
- Biological Relevance and Causal Support
- Direction and Degree of Desired Target Modulation
- Tissue Distribution and Accessible Disease Compartments
- Target Redundancy and Functional Compensation
- Human Evidence and Preclinical Evidence Weighting
- Anticipated Safety Liabilities
- Modality Compatibility and Delivery Feasibility
- Availability of Assays and Experimental Models
- Competitive Landscape and Differentiation Potential
- Transparent Scoring and Decision-Making Under Uncertainty
8Experimental Target Validation10 argomenti
- Genetic Perturbation and Pharmacological Perturbation
- Orthogonal Approaches to the Same Target Hypothesis
- Acute and Chronic Target Modulation
- Rescue Experiments and Causal Interpretation
- Target Dosage and Partial Modulation
- Cell-Type-Specific and Context-Dependent Effects
- On-Target Activity and Secondary Biological Responses
- Reproducibility Across Models and Laboratories
- Negative Findings and Target Hypothesis Revision
- Defining Target Validation Milestones and Stop Criteria
9Target Tractability and Modality Selection10 argomenti
- Druggability and Biological Validity as Separate Questions
- Binding Pockets, Surfaces, and Molecular Accessibility
- Intracellular and Extracellular Targets
- Catalytic, Scaffolding, and Regulatory Functions
- Inhibition, Activation, Replacement, and Depletion Strategies
- Small-Molecule and Biologic Access Constraints
- Transient and Durable Therapeutic Interventions
- Target Abundance, Turnover, and Required Exposure
- Delivery Barriers and Tissue Selectivity
- Selecting a Modality from the Intended Therapeutic Mechanism
Tappa 2
Models, Assays & Screening
Saggi, screening e i loro artefatti
18 moduli · 180 argomenti
10Chemical Probes and Research Reagents10 argomenti
- Probe Quality and Fitness for Purpose
- Potency, Selectivity, and Cellular Activity
- Negative Controls and Inactive Analogues
- Orthogonal Probes with Distinct Chemical Structures
- Concentration-Dependent Interpretation
- Reagent Identity, Purity, and Stability
- Antibody and Protein Reagent Validation
- Tool Compounds and Development Candidates
- Availability of Reliable Target Engagement Evidence
- Avoiding Mechanistic Conclusions from Inadequate Reagents
11Disease Model Selection and Qualification10 argomenti
- Fit-for-Purpose Models and Research Questions
- Construct, Face, and Predictive Validity
- Model Relevance to the Intended Patient Population
- Cell Lines and Disease-Specific Limitations
- Genetic Background and Environmental Context
- Model Phenotypes and Clinical Endpoints
- Positive Controls and Known Therapeutic Responses
- Biological Variability and Reproducibility
- Model Qualification Before Candidate Ranking
- Limits of Extrapolating Model Success to Clinical Benefit
12Primary Cells and Stem-Cell-Derived Models10 argomenti
- Primary Human Cells and Donor Variability
- Patient-Derived Materials and Clinical Annotation
- Induced Pluripotent Stem Cell Models
- Differentiation State and Functional Maturity
- Isogenic Comparisons and Background Effects
- Cell Identity and Phenotype Stability
- Culture-Induced Changes and Disease Fidelity
- Scaling Human Cell Models for Discovery
- Consent, Provenance, and Access to Biospecimens
- Integrating Human Cell Evidence into Candidate Decisions
13Organoids, Tissue Models, and Microphysiological Systems10 argomenti
- Three-Dimensional Models and Tissue Architecture
- Organoids and Patient-Derived Disease Models
- Organ-on-Chip Platforms and Controlled Microenvironments
- Multicellular Interactions and Stromal Components
- Perfusion, Mechanical Cues, and Tissue Function
- Model Access for Drug Delivery and Measurement
- Compound Distribution Within Complex Models
- Readout Standardization and Between-Batch Variability
- Benchmarking Against Human and Clinical Data
- Appropriate Uses and Remaining Predictive Limitations
14In Vivo Models in Discovery10 argomenti
- Selecting Models for Efficacy and Mechanistic Questions
- Spontaneous, Induced, and Genetically Defined Disease Models
- Species Differences in Target and Pathway Biology
- Disease Stage and Intervention Timing
- Exposure Confirmation and Pharmacodynamic Readouts
- Randomization, Blinding, and Prespecified Analyses
- Biological Sex, Age, and Background Effects
- Welfare, Replacement, Reduction, and Refinement Principles
- Replication and Cross-Model Confirmation
- Translational Interpretation of Positive and Negative Findings
15Assay Cascades and Discovery Decision Architecture10 argomenti
- Primary Screens and Follow-Up Assays
- Orthogonal Confirmation and Counterscreens
- Biochemical, Cellular, and Organism-Level Evidence
- Throughput and Biological Relevance Tradeoffs
- Assay Sequencing to Reduce False Positives
- Early Developability and Safety Filters
- Data Integration Across Different Readouts
- Compound Progression Criteria
- Iterative Refinement of the Assay Cascade
- Linking Assay Results to the Therapeutic Hypothesis
16Biochemical Assay Development10 argomenti
- Enzyme Activity and Reaction-Based Readouts
- Substrate Selection and Assay Context
- Initial Rates and Endpoint Measurements
- Assay Dynamic Range and Signal Stability
- Coupled Assays and Reagent Dependencies
- Controls for Direct Readout Interference
- Reproducibility and Plate-Level Variation
- Concentration-Response Curve Interpretation
- Apparent Potency and Assay Condition Dependence
- Qualification of Biochemical Assays for Screening
17Binding and Biophysical Characterization10 argomenti
- Affinity, Kinetics, and Binding Stoichiometry
- Association and Dissociation Rates
- Surface-Based and Solution-Based Measurements
- Thermal Stability and Binding-Related Shifts
- Calorimetric and Spectroscopic Binding Concepts
- Competition and Cooperative Binding
- Immobilization Effects and Experimental Artifacts
- Binding to Intended and Unintended Molecular States
- Orthogonal Confirmation of Physical Interaction
- Distinguishing Binding from Functional Modulation
18Cell-Based Functional Assays10 argomenti
- Endogenous and Engineered Cellular Readouts
- Reporter Systems and Biological Relevance
- Proximal and Distal Pathway Measurements
- Cell Permeability and Intracellular Availability
- Target Expression and Assay Sensitivity
- Cell Viability and Nonspecific Activity
- Time-Dependent Responses and Adaptation
- Culture Conditions and Apparent Drug Effects
- Phenotype Rescue and Functional Relevance
- Connecting Cellular Activity to Target Engagement
19High-Content and Imaging-Based Screening10 argomenti
- Multiparametric Cellular Phenotypes
- Image Acquisition and Biological Resolution
- Cell Segmentation and Feature Extraction
- Morphological Signatures and Phenotypic Similarity
- Subcellular Localization and Spatial Responses
- Time-Lapse Imaging and Dynamic Phenotypes
- Batch Effects and Image Analysis Bias
- Interpretable Features and Learned Representations
- Hit Selection from Complex Phenotypic Data
- Biological Confirmation Beyond Imaging Signatures
20High-Throughput Screening10 argomenti
- Screening Libraries and Chemical Diversity
- Assay Miniaturization and Automation
- Plate Layouts and Control Placement
- Assay Quality Metrics and Z-Prime Factor
- Normalization and Batch Correction
- Hit Thresholds and False Discovery Risk
- Compound Handling and Sample Integrity
- Primary Screening and Confirmation Strategy
- Data Traceability from Library Member to Result
- Evaluating Screen Quality Before Advancing Hits
21Hit Confirmation and Artifact Elimination10 argomenti
- Compound Identity and Purity Verification
- Independent Resupply and Activity Reconfirmation
- Concentration-Response Reproducibility
- Aggregation and Nonspecific Inhibition
- Fluorescence, Luminescence, and Detection Interference
- Reactive Chemistry and Assay Component Modification
- Cytotoxicity and General Stress Responses
- Promiscuous Activity and Frequent-Hitter Patterns
- Orthogonal Mechanistic and Biophysical Evidence
- Selecting Credible Starting Points for Optimization
22Phenotypic Drug Discovery10 argomenti
- Disease-Relevant Phenotypes Without a Preselected Target
- Rescue, Suppression, and State-Transition Readouts
- Phenotypic Screens in Human-Derived Models
- Multiparametric Efficacy and Toxicity Profiles
- Known Mechanism Comparators
- Phenotype Robustness Across Biological Contexts
- Hit Prioritization Without Complete Mechanistic Knowledge
- Linking Phenotypic Activity to Exposure
- Mechanistic Uncertainty and Development Risk
- When Phenotypic Evidence Supports Further Investment
23Target Deconvolution and Mechanism of Action10 argomenti
- Direct Binding Partners and Downstream Responders
- Chemoproteomic Approaches to Target Identification
- Genetic Sensitivity and Resistance Evidence
- Affinity Capture and Competition Concepts
- Thermal and Stability-Based Engagement Methods
- Perturbation Signatures and Pathway Inference
- Distinguishing Primary and Secondary Mechanisms
- Polypharmacology and Multiple Relevant Targets
- Causal Confirmation of the Proposed Mechanism
- Communicating Residual Mechanistic Uncertainty
24Fragment-Based Discovery10 argomenti
- Fragment Libraries and Low-Complexity Starting Points
- Detecting Weak but Specific Interactions
- Ligand Efficiency and Related Metrics
- Orthogonal Fragment Hit Confirmation
- Structural Information for Fragment Progression
- Fragment Growing, Linking, and Merging
- Maintaining Binding Quality During Molecular Expansion
- Solubility and Assayability Constraints
- From Fragment Hits to Lead-Like Molecules
- Evaluating Fragment Campaign Progress and Failure Modes
25Encoded and Display-Based Discovery Libraries10 argomenti
- DNA-Encoded Small-Molecule Libraries
- Phage and Other Display Platforms
- Selection-Based and Functional Screening Approaches
- Library Diversity and Representation
- Target Presentation and Selection Bias
- Enrichment and Binding Specificity
- Sequence or Barcode Identification
- Resynthesis and Off-Platform Confirmation
- Affinity Improvement and Functional Validation
- Limits of Inferring Drug Potential from Selection Enrichment
26Natural Products and Biologically Derived Leads10 argomenti
- Natural Product Chemical Diversity
- Extract-Based and Purified Compound Screening
- Dereplication and Known Compound Identification
- Activity-Guided Fractionation Concepts
- Mixture Effects and Misleading Activity Attribution
- Structural Elucidation and Identity Confirmation
- Supply, Synthesis, and Reproducibility Constraints
- Semisynthetic Optimization and Analogue Development
- Mechanistic Validation of Natural Product Leads
- Converting Biological Origin into a Reproducible Drug Program
27Drug Repurposing and Translational Repositioning10 argomenti
- New Indications for Existing Compounds
- Mechanism-Based and Phenotype-Based Repositioning
- Prior Human Exposure and Safety Evidence
- Formulation and Dose Differences Across Indications
- Tissue Exposure at Clinically Feasible Doses
- Biomarker and Patient Selection Opportunities
- Evidence Gaps Despite Previous Approval
- Intellectual Property and Commercial Feasibility
- Clinical Proof-of-Concept Strategy
- Distinguishing Plausible Repurposing from Unsupported Therapeutic Claims
Tappa 3
Molecular Design & Medicinal Chemistry
Cosa rende una molecola un farmaco
14 moduli · 140 argomenti
28Structure-Based Drug Design10 argomenti
- Experimental Structures and Structural Confidence
- Binding Site Geometry and Molecular Recognition
- Protein Flexibility and Alternative Conformations
- Water Networks and Solvation Effects
- Ligand Pose Interpretation
- Structure-Guided Optimization of Interactions
- Selectivity from Structural Differences
- Structural Limitations in Membrane and Disordered Targets
- Combining Structural and Functional Data
- Avoiding Overinterpretation of a Single Static Structure
29Virtual Screening and Computational Prioritization10 argomenti
- Ligand-Based and Structure-Based Screening
- Chemical Representations and Molecular Similarity
- Docking Scores and Pose Uncertainty
- Pharmacophore Models and Interaction Requirements
- Binding Energy Estimation Concepts
- Library Preparation and Molecular State Assignment
- Prospective Enrichment and Experimental Validation
- Applicability Domains and Dataset Bias
- Diversity-Aware Compound Selection
- Using Computation to Prioritize Experiments Rather Than Confirm Activity
30Machine Learning and AI-Assisted Discovery10 argomenti
- Prediction Tasks Across the Discovery Pipeline
- Assay Data Quality and Label Reliability
- Molecular Property and Activity Prediction
- Generative Design and Constraint Handling
- Protein Structure Predictions in Discovery Workflows
- Data Leakage and Misleading Retrospective Performance
- Out-of-Distribution Generalization
- Uncertainty-Aware and Active Learning Approaches
- Prospective Experimental Evaluation
- Reproducibility, Traceability, and Human Review of Model Proposals
31Medicinal Chemistry and Structure-Activity Relationships10 argomenti
- Chemical Series and Matched Molecular Comparisons
- Potency Trends and Activity Cliffs
- Substituent Effects on Binding and Function
- Stereochemistry and Biological Activity
- Bioisosteric Replacement Concepts
- Conformational Restriction and Molecular Flexibility
- Synthetic Accessibility and Iteration Speed
- Multiple Property Optimization
- Interpreting SAR with Assay and Structural Evidence
- Selecting Robust Chemical Series for Lead Development
32Physicochemical Properties and Drug-Like Behavior10 argomenti
- Solubility and Dissolution in Relevant Environments
- Lipophilicity and Distribution Coefficients
- Ionization and pKa
- Molecular Size, Polarity, and Hydrogen Bonding
- Permeability and Membrane Partitioning
- Solid-State Form and Physical Stability
- Chemical Stability and Reactive Liabilities
- Property Tradeoffs Across Therapeutic Modalities
- Empirical Guidelines and Their Applicability Limits
- Connecting Molecular Properties to Exposure and Formulation Feasibility
33Selectivity and Polypharmacology10 argomenti
- On-Target and Off-Target Activity Profiles
- Selectivity Within Protein Families
- Binding Selectivity and Functional Selectivity
- Tissue Context and Effective Selectivity
- Secondary Pharmacology Panels
- Beneficial and Undesirable Multi-Target Effects
- Concentration-Dependent Loss of Selectivity
- Translating Selectivity Margins into Exposure Context
- Distinguishing Mechanistic Toxicity from Promiscuous Activity
- Designing an Evidence-Based Selectivity Strategy
34Enzyme-Targeted Drug Discovery10 argomenti
- Catalytic Mechanisms and Therapeutic Intervention Points
- Competitive and Noncompetitive Inhibition Concepts
- Allosteric Modulation of Enzyme Activity
- Reversible and Time-Dependent Inhibition
- Substrate Concentration and Apparent Potency
- Cofactors and Assay Context
- Enzyme Turnover and Duration of Effect
- Selectivity Across Related Enzymes
- Cellular Substrate and Product Readouts
- Connecting Enzyme Modulation to Disease-Relevant Outcomes
35Receptor-Targeted Drug Discovery10 argomenti
- Agonism, Antagonism, and Partial Agonism
- Constitutive Activity and Inverse Agonism
- Orthosteric and Allosteric Binding
- Receptor Reserve and Assay Sensitivity
- Pathway Bias and Functional Readout Dependence
- Receptor Internalization and Desensitization
- Ligand Binding Kinetics and Effect Duration
- Selectivity Across Receptor Subtypes
- Native Tissue Context and Receptor Expression
- Translating Receptor Pharmacology into a Candidate Profile
36Ion Channel and Transporter Discovery10 argomenti
- Channel Gating and State-Dependent Modulation
- Transporter Function and Substrate Competition
- Electrophysiological and Surrogate Readouts
- Use Dependence and Kinetic Effects
- Membrane Potential and Assay Context
- Selectivity Across Related Channels and Transporters
- Tissue Distribution and Safety Relevance
- Cell-Based Confirmation of Functional Modulation
- Exposure Requirements at the Relevant Membrane Compartment
- Balancing Therapeutic Activity with Excitability-Related Risk
37Protein-Protein Interaction Modulators10 argomenti
- Interaction Interfaces and Hot Spots
- Stabilization and Disruption of Molecular Complexes
- Shallow Surfaces and Nontraditional Binding Sites
- Small Molecules, Peptides, and Biologic Approaches
- Conformational Dynamics of Interaction Partners
- Assay Design for Complex Formation
- Binding and Functional Consequences
- Intracellular Access and Target Engagement
- Selectivity Among Related Interaction Networks
- Demonstrating Disease-Relevant Modulation of a Protein Complex
38Covalent Drug Discovery10 argomenti
- Reversible and Irreversible Covalent Engagement
- Recognition-Driven and Nonspecific Reactivity
- Target Residue Accessibility and Context
- Time-Dependent Potency and Engagement Kinetics
- Target Turnover and Duration of Activity
- Proteome-Wide Selectivity Assessment
- Reactive Metabolites and Safety Concerns
- Cellular Confirmation of Covalent Engagement
- Exposure-Engagement Relationships
- Balancing Durable Activity with Chemical and Biological Selectivity
39Targeted Protein Degradation and Proximity-Induced Medicines10 argomenti
- Event-Driven and Occupancy-Driven Pharmacology
- Heterobifunctional Degraders and Molecular Glues
- Ternary Complex Formation and Cooperativity
- Degradation Potency and Maximum Effect
- Protein Resynthesis and Recovery Kinetics
- Tissue Context and Machinery Availability
- Selectivity Beyond Simple Binary Binding
- Permeability and Molecular Property Challenges
- Resistance and Mechanistic Confirmation
- Emerging Proximity-Induced Functions Beyond Degradation
40Small-Molecule Targeting of RNA and Gene Regulation10 argomenti
- RNA Structure and Accessible Binding Features
- Transcript-Specific and Context-Dependent Recognition
- Splicing Modulation as a Therapeutic Strategy
- RNA Stability and Translation Modulation
- RNA-Protein Complexes as Intervention Points
- Cellular RNA Abundance and Target Availability
- Selectivity Across the Transcriptome
- Direct Binding and Downstream Expression Effects
- Transcript-Level and Protein-Level Confirmation
- Connecting RNA Modulation to Therapeutic Benefit
41Peptide and Macrocyclic Therapeutics10 argomenti
- Linear, Cyclic, and Constrained Peptide Architectures
- Binding Surface Recognition and Specificity
- Proteolytic Stability and Half-Life
- Cell Penetration and Tissue Access
- Conformational Control and Cyclization
- Chemical Modification and Conjugation Strategies
- Solubility and Aggregation Liabilities
- Route of Administration and Formulation Constraints
- Functional Optimization and Developability
- Comparing Peptides with Small-Molecule and Protein Alternatives
Tappa 4
Biologics & Advanced Modalities
Anticorpi, RNA, cellule, coniugati
17 moduli · 170 argomenti
42Recombinant Protein Therapeutics10 argomenti
- Replacement, Supplementation, and Modulation Strategies
- Protein Sequence and Functional Domain Design
- Folding and Structural Integrity
- Post-Translational Modifications and Biological Activity
- Proteolysis, Aggregation, and Stability
- Half-Life Extension Concepts
- Tissue Distribution and Receptor Interactions
- Potency and Mechanism-Relevant Characterization
- Immunogenicity and Endogenous Protein Relationships
- Connecting Molecular Design to a Practical Therapeutic Product
43Therapeutic Antibody Discovery10 argomenti
- Antigen Selection and Biological Relevance
- Epitope Accessibility and Functional Consequences
- Antibody Discovery Platforms
- Binding Affinity and Kinetic Profiles
- Functional Screening Beyond Antigen Binding
- Agonistic, Antagonistic, and Depleting Mechanisms
- Cross-Species Reactivity and Development Models
- Sequence Diversity and Candidate Families
- Early Liability Screening
- Selecting Antibody Leads Against the Target Product Profile
44Antibody Engineering and Optimization10 argomenti
- Humanization and Sequence Refinement
- Affinity Maturation and Functional Tradeoffs
- Fc-Mediated Effector Functions
- Fc Receptor Interactions and Recycling
- Half-Life and Exposure Engineering
- Aggregation, Solubility, and Self-Association
- Chemical Modification Hot Spots
- Immunogenicity-Related Sequence Assessment
- Format Selection and Administration Requirements
- Integrated Optimization of Activity, Safety, and Developability
45Bispecific and Multispecific Biologics10 argomenti
- Dual-Target and Multi-Target Therapeutic Rationale
- Molecular Geometry and Spatial Constraints
- Valency, Affinity, and Avidity
- Simultaneous and Sequential Target Engagement
- Cell Bridging and Conditional Activity
- Chain Pairing and Product Heterogeneity
- Tissue Distribution and Antigen Sink Effects
- Functional Potency and Context Dependence
- Safety Risks from Unintended Cellular Interactions
- Candidate Selection Across Complex Molecular Formats
46Antibody-Drug Conjugates and Targeted Payload Delivery10 argomenti
- Target Selection and Tissue Expression
- Antibody Internalization and Intracellular Trafficking
- Linker Stability and Release Mechanisms
- Payload Class and Biological Effect
- Drug-to-Antibody Ratio and Product Heterogeneity
- Bystander Activity and Tissue Context
- Systemic Exposure to Intact and Released Components
- Target-Dependent and Target-Independent Toxicity
- Resistance and Biomarker Strategy
- Integrating Antibody, Linker, and Payload Performance
47Therapeutic Enzymes and Enzyme Replacement10 argomenti
- Enzyme Activity as the Therapeutic Function
- Substrate Accessibility in Disease Compartments
- Intracellular Targeting and Uptake
- Cofactor Dependence and Physiological Conditions
- Circulating Stability and Tissue Retention
- Substrate Reduction and Biochemical Endpoints
- Immune Responses to Therapeutic Enzymes
- Enzyme Activity and Clinically Relevant Exposure
- Functional Comparability Across Product Variants
- Linking Biochemical Correction to Patient Benefit
48Cytokines, Growth Factors, and Immune-Modulating Proteins10 argomenti
- Receptor Networks and Pleiotropic Effects
- Potency, Selectivity, and Cell-Type Responses
- Short Half-Life and Exposure Constraints
- Local and Systemic Activity
- Engineered Receptor Bias and Conditional Activation
- Fusion Formats and Targeted Delivery Concepts
- Immune Activation and Safety Margins
- Pharmacodynamic Markers of Pathway Modulation
- Combination Opportunities and Interaction Risks
- Balancing Immune Function with Tolerability
49Oligonucleotide Therapeutics10 argomenti
- Antisense, RNA Interference, and Aptamer Modalities
- Sequence Recognition and Mechanism of Action
- Chemical Modifications and Stability
- Tissue Uptake and Intracellular Trafficking
- Endosomal Escape and Functional Availability
- Transcript Isoforms and Target Site Selection
- Sequence-Dependent and Sequence-Independent Effects
- Protein Binding and Distribution
- Duration of Gene Modulation
- Candidate Evaluation from Target Engagement to Functional Outcome
50mRNA-Based Therapeutic Platforms10 argomenti
- Encoded Protein and Therapeutic Rationale
- Transcript Design Attributes Relevant to Drug Development
- Translation, Persistence, and Protein Production
- Innate Immune Recognition and Biological Response
- Delivery Formulation and Tissue Distribution
- Transient Expression and Repeat Administration
- Protein Localization and Functional Activity
- Product Integrity and Impurity Considerations
- Exposure and Pharmacodynamic Measurement Challenges
- Linking Expression Profiles to a Therapeutic Window
51Gene Addition and Gene Replacement Therapies10 argomenti
- Therapeutic Gene Function and Disease Mechanism
- Vector and Nonvector Delivery Choices
- Tissue Tropism and Target Cell Access
- Expression Level, Duration, and Regulation
- Episomal Persistence and Genomic Integration Considerations
- Preexisting Immunity and Treatment Eligibility
- Biodistribution and Off-Tissue Expression
- Durability, Redosing, and Long-Term Follow-Up
- Potency and Functional Correction
- Connecting Product Design to a Clinically Meaningful Outcome
52Therapeutic Genome and Epigenome Editing10 argomenti
- In Vivo and Ex Vivo Treatment Architectures
- Correction, Disruption, and Regulatory Modification Goals
- Editing Modality and Disease-Specific Suitability
- Delivery to the Clinically Relevant Cell Population
- Mosaic Outcomes and Required Fraction of Corrected Cells
- Unintended Genomic and Cellular Consequences
- Persistence of Editing Components
- Functional Restoration and Long-Term Stability
- Patient Genotype and Treatment Eligibility
- Translational Evidence Beyond Editing Percentage Alone
53Cell-Based Therapeutic Products10 argomenti
- Autologous and Allogeneic Treatment Strategies
- Immune, Stem, and Differentiated Cell Modalities
- Cell Identity and Intended Biological Function
- Functional Engineering and Phenotype Stability
- Expansion, Persistence, and Tissue Localization
- Host Compatibility and Immune Rejection
- Uncontrolled Growth and Other Product-Specific Risks
- Potency Assays and Clinically Relevant Function
- Administration Logistics and Chain of Identity
- Linking Cellular Attributes to Safety and Clinical Performance
54Vaccine Discovery and Pharmaceutical Biotechnology10 argomenti
- Antigen Selection and Immune Response Goals
- Protein, Nucleic Acid, and Vector Platform Concepts
- Antigen Presentation and Immune Recognition
- Adjuvants and Formulation Contributions
- Neutralizing and Cellular Immune Readouts
- Correlates of Protection and Their Limitations
- Population, Age, and Prior Exposure Effects
- Immune Durability and Booster Rationale
- Preventive and Therapeutic Vaccine Development Differences
- Translating Immunogenicity into Evidence of Clinical Benefit
55Microbiome-Derived and Live Biotherapeutic Products10 argomenti
- Defined Organisms, Communities, and Microbial Products
- Mechanistic Hypotheses for Therapeutic Benefit
- Strain Identity and Functional Characterization
- Colonization, Persistence, and Transient Activity
- Host Context and Baseline Microbiome Variation
- Functional Metabolites and Pharmacodynamic Readouts
- Product Consistency and Biological Stability
- Safety Assessment in the Intended Patient Population
- Causal Evidence Beyond Community Composition Changes
- Clinical Evaluation of Product-Specific Benefit
56Radiopharmaceutical and Theranostic Discovery10 argomenti
- Molecular Targeting and Radionuclide Delivery
- Target Expression and Tissue Accessibility
- Ligand, Chelator, and Radionuclide Compatibility
- Binding, Internalization, and Retention
- Physical Decay and Biological Clearance
- Diagnostic Imaging and Patient Selection
- Tissue Dosimetry and Exposure Heterogeneity
- Therapeutic Index and Off-Target Irradiation
- Product Stability and Time-Sensitive Use Constraints
- Connecting Imaging Evidence to Therapeutic Development Decisions
57Drug Delivery and Tissue Targeting10 argomenti
- Biological Barriers Between Administration and Target
- Oral, Parenteral, Inhaled, and Local Delivery Concepts
- Tissue Permeability and Cellular Uptake
- Blood-Brain Barrier Access in Discovery Decisions
- Local Retention and Systemic Escape
- Targeted and Passive Distribution Mechanisms
- Release Kinetics and Exposure Duration
- Carrier-Drug Interactions and Product Stability
- Delivery-Related Toxicity and Immune Responses
- Evaluating Functional Delivery Rather Than Material Uptake Alone
58Nanomedicines and Delivery Formulations10 argomenti
- Lipid, Polymer, and Other Carrier Platforms
- Particle Size, Surface Properties, and Distribution
- Cargo Loading and Encapsulation Attributes
- Protein Corona and Biological Identity
- Intracellular Trafficking and Cargo Release
- Product Heterogeneity and Analytical Characterization
- Carrier and Cargo Pharmacokinetics
- Formulation Stability and Repeat-Dose Considerations
- Scale-Dependent Changes Relevant to Development
- Demonstrating the Contribution of the Delivery System
Tappa 5
Developability, Safety & Candidate Selection
Esposizione, sicurezza, il no netto
18 moduli · 180 argomenti
59Developability and Candidate Quality10 argomenti
- Potency and Efficacy Alongside Product Feasibility
- Solubility, Aggregation, and Physical Stability
- Chemical and Enzymatic Degradation
- Expression and Recovery Feasibility for Biologics
- Formulation Compatibility and Administration Constraints
- Product Heterogeneity and Characterization Burden
- Sequence and Structural Liabilities
- Supply, Synthetic Complexity, and Material Availability
- Ranking Candidates with Integrated Developability Data
- Identifying Liabilities Before Expensive Development Commitments
60Immunogenicity Assessment and Mitigation10 argomenti
- Product, Patient, and Treatment-Related Risk Factors
- Anti-Drug Antibodies and Neutralizing Responses
- Effects on Exposure, Activity, and Safety
- Sequence, Structure, and Aggregation Contributions
- Innate Immune Activation and Adaptive Responses
- Preclinical Models and Human Predictive Limitations
- Immunogenicity Assay Strategy and Drug Interference
- Clinical Sampling and Interpretation
- Comparing Binding Antibodies with Functional Consequences
- Risk Reduction Through Product Design and Evidence Review
61Discovery ADME and Metabolic Stability10 argomenti
- Absorption, Distribution, Metabolism, and Excretion in Candidate Selection
- Permeability and Transporter Interactions
- Plasma Protein Binding and Unbound Exposure
- Metabolic Stability in Relevant Biological Systems
- Metabolite Identification and Species Differences
- Enzyme Inhibition and Induction Liabilities
- Clearance Mechanisms and Tissue Distribution
- Biological Drug Catabolism and Recycling
- Early Prediction of Exposure-Limiting Properties
- Integrating ADME Findings into Molecular Optimization
62Bioanalytical Methods for Discovery and Development10 argomenti
- Analyte Definition Across Therapeutic Modalities
- Parent Drug, Metabolites, and Active Components
- Mass Spectrometric and Ligand-Binding Methods
- Total, Free, and Functionally Active Drug Measurements
- Matrix Effects and Sample Stability
- Sensitivity, Selectivity, and Quantification Range
- Reference Materials and Calibration
- Assay Qualification and Validation Concepts
- Interpretation of Below-Quantification Results
- Matching Bioanalytical Strategy to the Development Question
63Pharmacokinetics in Candidate Development10 argomenti
- Concentration-Time Profiles and Exposure Metrics
- Clearance, Volume of Distribution, and Half-Life
- Bioavailability and Route Dependence
- Dose Proportionality and Nonlinear Kinetics
- Tissue Exposure and Distribution Barriers
- Target-Mediated Drug Disposition
- Accumulation and Repeat Administration
- Species Differences and Human Exposure Prediction
- Population Variability and Covariate Effects
- Using PK Evidence to Compare and Progress Candidates
64Pharmacodynamics and Target Engagement10 argomenti
- Drug Presence and Biological Action
- Direct and Indirect Target Engagement Measurements
- Target Occupancy and Functional Response
- Proximal Biomarkers and Downstream Effects
- Response Delay and Biological Turnover
- Thresholds, Saturation, and Maximum Effect
- Reversible and Persistent Pharmacodynamic Changes
- Tissue-Specific Engagement and Sampling Limitations
- Separating Pharmacodynamic Activity from Clinical Efficacy
- Defining Evidence of Mechanism for a Development Program
65Exposure-Response and Translational Modeling10 argomenti
- Linking Exposure, Engagement, Response, and Outcome
- PK-PD Model Structures and Assumptions
- Hysteresis and Delayed Responses
- Disease Progression and Treatment Effects
- Mechanistic and Empirical Model Choices
- Parameter Uncertainty and Identifiability
- Allometric and Physiology-Based Translation Concepts
- Quantitative Systems Pharmacology Applications
- Prospective Model Evaluation
- Using Models to Inform Development Decisions with Explicit Limits
66Biomarker Discovery and Qualification10 argomenti
- Diagnostic, Prognostic, Predictive, and Pharmacodynamic Biomarkers
- Safety and Response Biomarkers
- Intended Context of Use
- Biological Rationale and Measurement Feasibility
- Analytical Validity and Clinical Validity
- Tissue, Blood, Imaging, and Digital Readouts
- Longitudinal Changes and Within-Patient Variability
- Biomarker Thresholds and Validation Populations
- Surrogate Endpoints and Evidence Requirements
- Translating Discovery Signals into Decision-Ready Biomarkers
67Companion Diagnostics and Patient Selection10 argomenti
- Treatment Eligibility and Biomarker-Defined Populations
- Diagnostic-Therapeutic Co-Development
- Assay Platform and Specimen Requirements
- Cutoff Selection and Classification Error
- Tumor and Tissue Heterogeneity
- Temporal Changes in Biomarker Status
- Diagnostic Performance and Treatment Effect Interpretation
- Retrospective and Prospective Validation
- Access, Turnaround Time, and Clinical Workflow
- Aligning Diagnostic Evidence with the Therapeutic Claim
68Preclinical Efficacy and Proof of Concept10 argomenti
- Prespecified Efficacy Questions and Success Criteria
- Model Choice and Mechanistic Relevance
- Clinically Relevant Comparators
- Exposure Confirmation in Efficacy Studies
- Dose-Response and Time-Course Evidence
- Biomarker and Functional Outcome Integration
- Durability and Reversibility of Benefit
- Replication Across Models and Biological Contexts
- Negative Results and Alternative Explanations
- Defining a Credible Preclinical Proof-of-Concept Package
69Safety Pharmacology and Secondary Pharmacology10 argomenti
- Functional Effects on Vital Physiological Systems
- Cardiovascular, Respiratory, and Nervous System Risk Questions
- Off-Target Activity and Mechanistic Follow-Up
- Exposure Margins and Unbound Drug Considerations
- Acute and Delayed Functional Effects
- In Vitro and In Vivo Evidence Integration
- Modality-Specific Safety Concerns
- Species Relevance and Interpretation Limits
- Follow-Up Studies Driven by Observed Signals
- Integrating Functional Safety Findings into Candidate Selection
70Toxicology Strategy for Drug Development10 argomenti
- Hazard Identification and Exposure Context
- Single and Repeated Administration Studies
- Target Organs and Reversibility of Findings
- Genotoxicity and Carcinogenicity Questions
- Reproductive and Developmental Risk Assessment
- Local Tolerance and Administration-Related Effects
- Biologic and Advanced Modality Considerations
- Immunotoxicity and Immune-Mediated Findings
- Study Design Based on Product and Intended Clinical Use
- Weight-of-Evidence Interpretation of Toxicological Risk
71Human-Relevant Safety Models and New Approach Methodologies10 argomenti
- Human Cell Models for Toxicity Assessment
- Organotypic Systems and Tissue Chips
- Mechanistic Toxicity Readouts
- In Silico Safety Predictions
- Exposure Matching Across Experimental Systems
- Benchmarking Against Known Human Outcomes
- Applicability Domains and Model Qualification
- Integrating Multiple Nonclinical Evidence Streams
- Opportunities to Reduce Animal Use
- Regulatory Acceptance as a Context-Specific Evidence Question
72Species Relevance and Translational Uncertainty10 argomenti
- Target Sequence and Functional Conservation
- Differences in Tissue Expression and Pathway Biology
- Cross-Reactivity of Biologic Candidates
- Species-Specific Metabolites and Exposure
- Immune Responses to Human Therapeutic Proteins
- Disease Model and Safety Model Differences
- Surrogate Molecules and Their Limitations
- Human Data Anchors for Translation
- Remaining Unknowns Before Human Studies
- Documenting Assumptions and Alternative Development Scenarios
73Translational Dose and Regimen Selection10 argomenti
- Integrating Nonclinical Exposure and Response Evidence
- Safety-Based and Pharmacology-Based Starting Dose Concepts
- Minimum Anticipated Biological Effect Level Concepts
- Exposure Margins and Uncertainty Factors
- Escalation Strategy and Predicted Active Exposure
- Duration of Effect and Dosing Interval
- Loading and Maintenance Regimen Rationale
- Route and Formulation Effects on Regimen Choice
- Updating Predictions with Emerging Human Data
- Documented Justification for Protocol-Level Dosing Decisions
74Development Candidate Nomination10 argomenti
- Candidate Selection Criteria and Evidence Completeness
- Potency, Selectivity, and Mechanistic Confidence
- Exposure and Efficacy at Feasible Administration Conditions
- Preliminary Safety and Therapeutic Window
- Developability and Material Supply Feasibility
- Biomarker and Patient Selection Readiness
- Primary and Backup Candidate Strategies
- Unresolved Liabilities and Mitigation Plans
- Cross-Functional Review and Go-or-No-Go Decisions
- Transition from Discovery Optimization to Formal Development
75Pharmaceutical Development and CMC Interfaces10 argomenti
- Drug Substance and Drug Product Definitions
- Critical Quality Attributes Relevant to Clinical Performance
- Formulation Selection and Product Presentation
- Analytical Characterization and Product Specifications
- Impurity Profiles and Safety Assessment Interfaces
- Stability and Shelf-Life Development
- Process Changes and Clinical Material Comparability
- Reference Standards and Potency Methods
- Clinical Supply Readiness and Product Accountability
- Handoff to Detailed Bioprocessing and Manufacturing Development
76Preparing the First Clinical Development Package10 argomenti
- Integrated Pharmacology and Toxicology Evidence
- Product Quality and Clinical Material Documentation
- Proposed Clinical Protocol and Monitoring Strategy
- Investigator Information and Known Risk Communication
- Gaps Requiring Resolution Before Human Exposure
- Interaction Between Scientific and Regulatory Teams
- IND and Clinical Trial Application Concepts
- Agency Scientific Advice and Development Questions
- Readiness Review Across Product, Evidence, and Operations
- Maintaining Traceability from Preclinical Claims to Supporting Data
Tappa 6
Clinical Development & Regulation
Studi clinici, autorità, evidenze
11 moduli · 110 argomenti
77Early Clinical Development and First-in-Human Studies10 argomenti
- Primary Objectives of Initial Human Studies
- Healthy Volunteer and Patient Study Contexts
- Single and Multiple Ascending Dose Designs
- Safety Monitoring and Escalation Review
- Human Pharmacokinetics and Exposure Confirmation
- Pharmacodynamic and Target Engagement Readouts
- Food, Formulation, and Administration Questions
- Sentinel and Staggered Enrollment Concepts
- Stopping Rules and Emerging Risk Assessment
- Updating the Development Hypothesis from Early Human Evidence
78Clinical Proof of Concept and Phase II Development10 argomenti
- Demonstrating Activity in the Intended Patient Population
- Dose and Regimen Exploration
- Endpoint Selection and Measurement Sensitivity
- Biomarker-Enriched and Unselected Populations
- Comparator and Background Therapy Selection
- Treatment Duration and Follow-Up
- Exposure-Response Evidence in Patients
- Efficacy Signals and Uncertainty
- Understanding Negative or Inconclusive Results
- Criteria for Progression to Confirmatory Development
79Confirmatory Clinical Development10 argomenti
- Translating Product Claims into Trial Objectives
- Clinically Meaningful Endpoints
- Active and Placebo Comparator Considerations
- Background Standard of Care
- Population Definition and External Validity
- Adequate Follow-Up for Benefit and Risk
- Trial Consistency Across Regions and Sites
- Confirmatory Evidence and Supportive Evidence
- Product Quality Consistency During Clinical Development
- Integrating Results into an Overall Benefit-Risk Assessment
80Clinical Trial Design and Statistical Interpretation10 argomenti
- Randomization, Blinding, and Allocation Concealment
- Hypotheses, Effect Sizes, and Statistical Power
- Estimands and Intercurrent Events
- Missing Data and Sensitivity Analyses
- Multiplicity and Hierarchical Testing
- Time-to-Event and Repeated-Measure Outcomes
- Interim Analyses and Adaptive Features
- Statistical Significance and Clinical Relevance
- Subgroup Findings and Interaction Evidence
- Prespecification, Transparency, and Reproducible Analysis
81Precision Trials and Special Development Contexts10 argomenti
- Biomarker-Stratified and Enrichment Designs
- Basket, Umbrella, and Platform Trial Concepts
- Rare Disease and Small Population Constraints
- Natural History Data and External Controls
- Pediatric Development and Age-Appropriate Evidence
- Older Adults and Comorbidity Representation
- Organ Impairment and Exposure Variability
- Durable Interventions and Long-Term Follow-Up
- Individualized Therapies and Product Variability
- Matching Design Innovation to the Evidence Question
82Clinical Operations, Ethics, and Data Quality10 argomenti
- Informed Consent and Participant Understanding
- Ethics Review and Independent Oversight
- Site Selection and Investigator Readiness
- Recruitment, Retention, and Representative Enrollment
- Protocol Feasibility and Participant Burden
- Investigational Product Handling and Accountability
- Risk-Based Monitoring and Data Verification
- Safety Reporting and Escalation Responsibilities
- Privacy, Data Governance, and Research Integrity
- Trial Registration and Responsible Results Disclosure
83Regulatory Development and Evidence Strategy10 argomenti
- Product Classification and Development Jurisdictions
- Drug, Biologic, and Combination Product Interfaces
- Regulatory Advice and Milestone Planning
- Nonclinical, Clinical, and Quality Evidence Integration
- Common Technical Document Organization Concepts
- Scientific Justification for Development Deviations
- Expedited Programs and Their Evidence Expectations
- Proposed Labeling and Supported Product Claims
- Agency Questions and Benefit-Risk Uncertainty
- Lifecycle Commitments After Initial Authorization
84Integrated Benefit-Risk and Clinical Value Assessment10 argomenti
- Magnitude and Durability of Therapeutic Benefit
- Severity, Frequency, and Reversibility of Harm
- Disease Context and Available Alternatives
- Patient Preferences and Treatment Burden
- Subpopulation Differences in Benefit and Risk
- Uncertainty from Trial Design and Evidence Gaps
- Absolute and Relative Effect Interpretation
- Generalizability to Clinical Practice
- Risk Mitigation and Monitoring Requirements
- Transparent Communication of the Overall Evidence
85Pharmacovigilance and Post-Authorization Evidence10 argomenti
- Known Risks, Potential Risks, and Missing Information
- Adverse Event Reports and Signal Detection
- Exposure Denominators and Reporting Bias
- Causality Assessment and Confounding
- Registries and Long-Term Follow-Up
- Real-World Data and Fit-for-Purpose Study Design
- Rare and Delayed Adverse Effects
- Product Quality Signals and Clinical Safety Interfaces
- Risk Management Plans and Label Updates
- Feeding Post-Authorization Findings Back into Research
86Biosimilars, Comparability, and Product Lifecycle Development10 argomenti
- Biosimilarity and Reference Product Selection
- Analytical Similarity and Functional Characterization
- Residual Uncertainty and Evidence Integration
- Clinical Pharmacology and Comparative Evidence
- Immunogenicity Considerations in Product Comparison
- Manufacturing Changes and Comparability
- Formulation Changes and New Presentations
- Indication Extrapolation as a Scientific Question
- Product-Specific and Jurisdiction-Specific Requirements
- Maintaining Clinical Confidence Throughout the Product Lifecycle
87Resistance, Combination Therapies, and Treatment Evolution10 argomenti
- Intrinsic and Acquired Resistance Mechanisms
- Target Alteration and Pathway Compensation
- Cellular State Changes and Tissue Microenvironment
- Rational Combination Hypotheses
- Additivity, Synergy, and Antagonism
- Combination Exposure and Safety Interactions
- Scheduling and Sequence of Administration
- Biomarkers of Response and Resistance
- Demonstrating Each Component's Contribution
- Using Treatment Failure to Refine Discovery Programs
Tappa 7
Portfolio, Partnerships & Capstone
Brevetti, partner, il tuo programma
3 moduli · 30 argomenti
88Intellectual Property and Discovery Portfolio Strategy10 argomenti
- Composition, Use, and Platform Intellectual Property
- Patentability and Freedom-to-Operate Questions
- Data, Materials, and Reagent Ownership
- Licensing and Collaboration Terms as Development Constraints
- Competitive Target and Modality Landscapes
- Scientific Differentiation and Product Differentiation
- Portfolio Balance Across Stages and Risk Types
- Kill Criteria and Opportunity Cost
- Backup Programs and Shared Platform Dependencies
- Evaluating Assets with Transparent Scientific Assumptions
89Translational Project Management and Partnerships10 argomenti
- Integrated Development Plans and Critical Paths
- Milestone-Based Budgets and Resource Allocation
- Academic-to-Industry Technology Transfer
- CRO, CDMO, Diagnostic, and Clinical Partner Interfaces
- Work Package Specifications and Acceptance Criteria
- Data Quality, Reproducibility, and Vendor Oversight
- Cross-Functional Decision Meetings
- Funding Requirements Across Development Stages
- Scientific Due Diligence and Evidence Rooms
- Preserving Knowledge and Accountability Across Collaborations
90Integrated Drug Discovery and Development Projects10 argomenti
- Target Validation Plan Anchored in Human Disease Evidence
- Assay Cascade for a Defined Therapeutic Hypothesis
- Hit-to-Lead Strategy with Artifact and Selectivity Controls
- Candidate Comparison Using Potency, Exposure, Safety, and Developability
- Therapeutic Antibody Program from Epitope to Product Profile
- RNA-Based Therapy Assessment with Delivery and Functional Readouts
- Translational Biomarker Plan Connecting Models to Patients
- Preclinical-to-Clinical Readiness Review for a New Candidate
- Clinical Proof-of-Concept Design with Prespecified Decision Criteria
- Integrated Review of Mechanism, Product Quality, Benefit, Risk, and Feasibility
Quindici minuti.Ogni giorno.
- 1
Una lezione entra nella pausa pranzo
Un'idea alla volta, in slide brevi. Una lezione intera dura circa quindici minuti.
- 2
Esercizi con correzione immediata
Le domande sono dentro la lezione. Rispondi e vedi subito se hai capito.
- 3
Una serie che ti fa tornare
Una lezione al giorno tiene viva la serie. Sessioni brevi e costanti ti portano fino in fondo.
- 1
Una lezione entra nella pausa pranzo
Un'idea alla volta, in slide brevi. Una lezione intera dura circa quindici minuti.
- 2
Esercizi con correzione immediata
Le domande sono dentro la lezione. Rispondi e vedi subito se hai capito.
- 3
Una serie che ti fa tornare
Una lezione al giorno tiene viva la serie. Sessioni brevi e costanti ti portano fino in fondo.
Per chi sta dietro la pipeline.
Biologi che entrano in un team discovery
Chimici che vogliono l'intera pipeline
Dove crescerai di più
Leggi le relazioni struttura-attività
Tappa 3 · Molecular Design & Medicinal ChemistryClinici che passano all'industria
Dove crescerai di più
Leggi onestamente un risultato di fase II
Tappa 6 · Clinical Development & Regulation
Dove porta questo corso.
Il lavoro attorno a cui è costruito questo corso, e come ci si entra.
Discovery Scientist
Esegue gli esperimenti che portano un programma da un bersaglio a una molecola candidata.
Tutte le carriere del futuroSul lavoro
- Costruire ed eseguire i saggi scelti da un progetto
- Distinguere i veri hit dagli artefatti del saggio
- Presentare i dati che chiudono o fanno avanzare una serie
Come ci si entra
Una laurea in biologia, chimica o farmacologia; molti ruoli a questo livello chiedono un dottorato o diversi anni al banco.
Sii il primo della lista.
Accesso anticipato per i singoli, pilota per i team. Dicci chi sta imparando.
enterprise@astratrainer.com